W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Key Timestamps

01:04 - Guest Introduction

03:45 - FDA Indication for Obesity

08:45 - SURMOUNT-2

17:40 - SURMOUNT-3 and -4

22:00 - Future of Incretin Therapies